We herein report a number of novel findings: a pilot clinical study suggesting the efficacy of MH in the treatment of AD as well as mechanistic data that support this clinical finding including down regulation of IL4‐induced CCL26 release from keratinocytes and inhibition of mast cells degranulation. The gene discussed is CCL26; the disease is Alzheimer disease.